Jubilant Pharmova Ltd
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]
- Market Cap ₹ 10,869 Cr.
- Current Price ₹ 682
- High / Low ₹ 724 / 300
- Stock P/E
- Book Value ₹ 147
- Dividend Yield 0.73 %
- ROCE 4.28 %
- ROE 2.68 %
- Face Value ₹ 1.00
Pros
- Company has been maintaining a healthy dividend payout of 99.4%
Cons
- Stock is trading at 4.63 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -24.5% over past five years.
- Company has a low return on equity of 6.75% over last 3 years.
- Earnings include an other income of Rs.67.0 Cr.
- Working capital days have increased from 36.7 days to 155 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2,633 | 3,142 | 3,666 | 3,172 | 2,656 | 2,491 | 3,306 | 3,439 | 3,140 | 2,710 | 88 | 810 | 779 | |
2,213 | 2,650 | 3,076 | 2,890 | 2,344 | 2,173 | 2,765 | 3,112 | 2,765 | 2,282 | 95 | 807 | 772 | |
Operating Profit | 420 | 492 | 590 | 282 | 312 | 318 | 541 | 326 | 375 | 427 | -7 | 3 | 6 |
OPM % | 16% | 16% | 16% | 9% | 12% | 13% | 16% | 9% | 12% | 16% | -8% | 0% | 1% |
-141 | -90 | -198 | 305 | 62 | 52 | 45 | 72 | 168 | 48 | 126 | 138 | 67 | |
Interest | 193 | 263 | 285 | 233 | 201 | 174 | 135 | 129 | 136 | 102 | 31 | 19 | 28 |
Depreciation | 132 | 152 | 175 | 107 | 87 | 81 | 83 | 86 | 107 | 100 | 6 | 43 | 47 |
Profit before tax | -46 | -13 | -68 | 246 | 86 | 115 | 368 | 183 | 299 | 273 | 82 | 79 | -1 |
Tax % | -76% | -238% | 101% | 17% | 16% | 31% | 28% | 20% | -7% | 21% | 5% | 37% | |
-81 | -43 | 1 | 205 | 73 | 79 | 263 | 148 | 321 | 214 | 78 | 50 | -32 | |
EPS in Rs | -5.08 | -2.72 | 0.05 | 12.88 | 4.58 | 4.97 | 16.54 | 9.27 | 20.16 | 13.46 | 4.93 | 3.13 | -1.99 |
Dividend Payout % | -59% | -110% | 5,652% | 23% | 65% | 60% | 18% | 49% | 25% | 37% | 101% | 160% |
Compounded Sales Growth | |
---|---|
10 Years: | -13% |
5 Years: | -25% |
3 Years: | -36% |
TTM: | -8% |
Compounded Profit Growth | |
---|---|
10 Years: | 0% |
5 Years: | -28% |
3 Years: | -47% |
TTM: | -135% |
Stock Price CAGR | |
---|---|
10 Years: | 16% |
5 Years: | 3% |
3 Years: | -5% |
1 Year: | 128% |
Return on Equity | |
---|---|
10 Years: | 8% |
5 Years: | 8% |
3 Years: | 7% |
Last Year: | 3% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 16 | 16 | 15 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
Reserves | 1,901 | 1,828 | 1,717 | 1,929 | 1,998 | 2,027 | 2,233 | 2,324 | 2,591 | 1,267 | 1,266 | 2,399 | 2,324 |
2,935 | 3,263 | 3,314 | 2,279 | 1,808 | 1,698 | 1,424 | 1,702 | 2,013 | 504 | 507 | 346 | 414 | |
1,322 | 1,385 | 1,604 | 963 | 507 | 651 | 951 | 821 | 814 | 58 | 41 | 248 | 261 | |
Total Liabilities | 6,174 | 6,492 | 6,651 | 5,188 | 4,329 | 4,391 | 4,625 | 4,864 | 5,433 | 1,845 | 1,829 | 3,008 | 3,014 |
1,840 | 2,185 | 2,151 | 1,446 | 1,415 | 1,421 | 1,438 | 1,491 | 1,865 | 127 | 124 | 687 | 686 | |
CWIP | 419 | 213 | 242 | 20 | 36 | 65 | 115 | 284 | 59 | 0 | 0 | 47 | 59 |
Investments | 1,960 | 1,979 | 2,006 | 1,766 | 1,709 | 1,710 | 1,706 | 1,764 | 1,764 | 1,646 | 1,646 | 1,657 | 1,657 |
1,955 | 2,114 | 2,251 | 1,955 | 1,169 | 1,195 | 1,365 | 1,325 | 1,746 | 71 | 60 | 618 | 613 | |
Total Assets | 6,174 | 6,492 | 6,651 | 5,188 | 4,329 | 4,391 | 4,625 | 4,864 | 5,433 | 1,845 | 1,829 | 3,008 | 3,014 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
406 | 827 | 549 | 286 | 164 | 419 | 558 | 182 | 317 | 608 | -4 | -65 | |
-502 | -399 | -194 | 1,319 | 522 | -43 | -127 | -285 | -198 | 178 | 93 | 31 | |
-686 | -446 | -361 | -1,647 | -784 | -338 | -470 | 85 | -41 | -782 | -107 | 23 | |
Net Cash Flow | -782 | -18 | -6 | -42 | -98 | 38 | -40 | -18 | 78 | 5 | -18 | -12 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 56 | 46 | 53 | 37 | 47 | 57 | 54 | 51 | 49 | 0 | 88 | 85 |
Inventory Days | 156 | 132 | 135 | 97 | 119 | 127 | 120 | 87 | 142 | 0 | 276 | |
Days Payable | 186 | 111 | 110 | 96 | 91 | 136 | 154 | 106 | 134 | 145 | ||
Cash Conversion Cycle | 26 | 67 | 77 | 38 | 75 | 47 | 21 | 32 | 58 | 0 | 88 | 216 |
Working Capital Days | 43 | 53 | -51 | 63 | 44 | 48 | 27 | 44 | 83 | -2 | -42 | 155 |
ROCE % | 7% | 8% | 9% | 6% | 7% | 7% | 14% | 8% | 10% | 12% | 6% | 4% |
Documents
Announcements
- Closure Of Manufacturing Operations Of Solid Dosage Formulation Facility Of Jubilant Cadista Pharmaceuticals Inc., USA ('Jubilant Cadista'), A Subsidiary, Located At Salisbury, Maryland, USA. Further, Following The Status Change Of Jubilant Generics Limited'S ('JGL') Roorkee Facility By USFDA To VAI, The Company Expects The Exports From The Roorkee Facility To The US Market To Increase In A Meaningful And Gradual Manner. 18 Apr
- USFDA Communication 17 Apr
- Compliance Certificate Under Regulation 40(10) Of The SEBI (LODR) Regulations, 2015 10 Apr
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 10 Apr
- Compliance Certificate For The Financial Year Ended March 31, 2024. 5 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Feb 2024TranscriptNotesPPT
-
Oct 2023TranscriptNotesPPT
-
Jul 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptPPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptPPT
-
Jun 2022TranscriptPPT
-
Mar 2022TranscriptNotesPPT
-
Jan 2022TranscriptPPT
-
Jul 2021TranscriptPPT
-
Jun 2021Transcript PPT
-
Jan 2021TranscriptPPT
-
Nov 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
Jun 2020Transcript PPT
-
Jan 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Oct 2018TranscriptPPT
-
Jul 2018TranscriptPPT
-
Jun 2018TranscriptNotesPPT
-
May 2018TranscriptPPT
-
Jan 2018TranscriptPPT
-
Oct 2017TranscriptPPT
-
Aug 2017TranscriptNotesPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
Jul 2016TranscriptPPT
-
May 2016TranscriptPPT
-
Jan 2016TranscriptPPT
Business Segments & Revenue Contribution 9MFY24[1][2]
a) Radiopharma (~44%): Radiopharmaceuticals (including radiopharmacies)The company is the #3 radiopharmaceutical manufacturer in the US and has the #2 network in the US with 46 radiopharmacies. In 9MFY24, sale of Mertiatide, Sulfur colloid) and Ruby-Fill did very well. RUBY-FILL is a cardiac imaging product. Company plans to maintain its leadership position in North America.[3]